Andrew Lister

5.5k total citations · 1 hit paper
40 papers, 1.8k citations indexed

About

Andrew Lister is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Andrew Lister has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 11 papers in Genetics and 10 papers in Oncology. Recurrent topics in Andrew Lister's work include Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Acute Lymphoblastic Leukemia research (5 papers). Andrew Lister is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Acute Lymphoblastic Leukemia research (5 papers). Andrew Lister collaborates with scholars based in United Kingdom, Canada and United States. Andrew Lister's co-authors include John Radford, Barry W. Hancock, Peter Hoskin, Paul Smith, A. Z. S. Rohatiner, Peter Johnson, Anthony J. Swerdlow, David C. Linch, Alan Horwich and David Cunningham and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Andrew Lister

40 papers receiving 1.8k citations

Hit Papers

Results of a Trial of PET-Directed Therapy for Early-Stag... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
    2015 407 citations John Radford, Tim Illidge et al. New England Journal of Medicine profile →

Peers

Andrew Lister
Louis F. Diehl United States
E. Maartense Netherlands
G. Schellong Germany
S Piantadosi United States
Graham P. Collins United Kingdom
Jamey Skillings Canada
Einar Hannisdal Norway
Milayna Subar United States
Maria Dall’Era United States
D.Th. Sleijfer Netherlands
Louis F. Diehl United States
Andrew Lister
Citations per year, relative to Andrew Lister Andrew Lister (= 1×) peers Louis F. Diehl

Countries citing papers authored by Andrew Lister

Since Specialization
Citations

This map shows the geographic impact of Andrew Lister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lister more than expected).

Fields of papers citing papers by Andrew Lister

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lister. The network helps show where Andrew Lister may publish in the future.

Co-authorship network of co-authors of Andrew Lister

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lister. A scholar is included among the top collaborators of Andrew Lister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lister. Andrew Lister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Radford, John, Tim Illidge, Nicholas Counsell, et al.. (2015). Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 372(17). 1598–1607. 407 indexed citations breakdown →
2.
Šalkovskis, Paul M., et al.. (2015). Screening for post-traumatic stress symptoms in looked after children. Journal of Children s Services. 10(4). 365–375. 14 indexed citations
3.
Swerdlow, Anthony J., Rosie Cooke, Andrew Bates, et al.. (2014). Risk of Premature Menopause After Treatment for Hodgkin’s Lymphoma. JNCI Journal of the National Cancer Institute. 106(9). 44 indexed citations
4.
Gibb, Adam, Alastair Greystoke, Malcolm Ranson, et al.. (2013). A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. British Journal of Cancer. 109(10). 2560–2565. 6 indexed citations
5.
Stevens, Jane, Rachel Waters, Shireen Kassam, et al.. (2011). Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. British Journal of Haematology. 154(4). 448–456. 17 indexed citations
6.
7.
Tsitsikas, Dimitris A., et al.. (2011). The attitudes of relatives to autopsy: a misconception. Journal of Clinical Pathology. 64(5). 412–414. 32 indexed citations
8.
Masir, Noraidah, Margaret T. Jones, Abigail M. Lee, et al.. (2010). The expression of Bcl‐2 by proliferating cells varies in different categories of B‐cell lymphoma. Histopathology. 56(5). 617–626. 2 indexed citations
9.
Intermesoli, Tamara, Jonathan Shamash, A. Z. S. Rohatiner, et al.. (2009). Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy. British Journal of Haematology. 147(3). 408–410. 1 indexed citations
10.
Pearce, Daniel J., Robert W. Wilkinson, Claire Crafter, et al.. (2009). AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo. Cancer Research. 69(10). 4150–4158. 62 indexed citations
11.
Stevens, Jane, et al.. (2009). Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre. British Journal of Haematology. 145(1). 40–44. 6 indexed citations
12.
Goff, Lindsey K., Karin E. Summers, Sameena Iqbal, et al.. (2009). Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma. Journal of Clinical Oncology. 27(36). 6094–6100. 29 indexed citations
13.
Treon, Steven P., Andrew R. Branagan, Leukothea Ioakimidis, et al.. (2008). Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 113(16). 3673–3678. 103 indexed citations
14.
Swerdlow, Anthony J., Craig Higgins, Paul Smith, et al.. (2007). Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. JNCI Journal of the National Cancer Institute. 99(3). 206–214. 318 indexed citations
15.
Jong, Daphne de, Andreas Rosenwald, Mukesh Chhanabhai, et al.. (2007). Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology. 25(7). 805–812. 233 indexed citations
16.
17.
Helbling, Daniel, Beatrice U. Mueller, Nikolai A. Timchenko, et al.. (2004). The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proceedings of the National Academy of Sciences. 101(36). 13312–13317. 71 indexed citations
18.
Lowndes, Sarah, et al.. (2002). Stevens–Johnson syndrome after treatment with rituximab. Annals of Oncology. 13(12). 1948–1950. 79 indexed citations
19.
Lister, Andrew, Lauren E. Abrey, & John T. Sandlund. (2002). Central Nervous System Lymphoma. Hematology. 2002(1). 283–296. 39 indexed citations
20.
Neat, Michael, Nicola Foot, Loretta M. Byrne, et al.. (2002). Comparative genomic hybridization and multiplex-fluorescence in situ hybridization: an appraisal in elderly patients with acute myelogenous leukemia. The Hematology Journal. 3(6). 290–298. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis F. Diehl Breakdown of academic impact, for papers by E. Maartense Breakdown of academic impact, for papers by G. Schellong Breakdown of academic impact, for papers by S Piantadosi Breakdown of academic impact, for papers by Graham P. Collins Breakdown of academic impact, for papers by Jamey Skillings Breakdown of academic impact, for papers by Einar Hannisdal Breakdown of academic impact, for papers by Milayna Subar Breakdown of academic impact, for papers by Maria Dall’Era Breakdown of academic impact, for papers by D.Th. Sleijfer
Rankless by CCL
2026